rs2872507 — IKZF3

IKZF3 17q21 — The Immunological Crossroads

The chromosome 17q21 region is one of the most intensively studied loci in immunogenetics. A dense block of over 130 SNPs in strong linkage disequilibrium spans six genes — IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA — and has been independently associated with asthma, rheumatoid arthritis, Crohn's disease, type 1 diabetes, Graves' disease, and primary biliary cholangitis. The rs2872507 variant sits within this regulatory haploblock and influences transcription levels of ORMDL3 and GSDMB¹¹ influences transcription levels of ORMDL3 and GSDMB
rs2872507 genotype correlates strongly with ORMDL3 gene expression in airway cells; GG=highest, AA=lowest expression in a genotype-dependent manner.

IKZF3 encodes Aiolos, a zinc finger transcription factor in the Ikaros family. Aiolos is essential for B cell maturation and plasma cell differentiation²² Aiolos is essential for B cell maturation and plasma cell differentiation
Aiolos regulates B cell activation and maturation, Th17 differentiation, and NK cell maturation and plays a non-redundant role in silencing IL-2 expression in developing Th17 cells³³ silencing IL-2 expression in developing Th17 cells
Aiolos binds directly to the IL-2 promoter and triggers chromatin modifications that shut down IL-2 transcription, promoting Th17 polarization, thereby facilitating Th17 differentiation. Dysregulated Aiolos activity could shift the balance toward pathological Th17 responses that drive multiple autoimmune conditions.

The Mechanism

rs2872507 is a regulatory variant⁴⁴ regulatory variant
An intergenic/regulatory SNP that modulates the expression of neighboring genes rather than changing a protein sequence embedded in a complex regulatory landscape. The A and G alleles are associated with differential chromatin accessibility and transcription factor binding at this locus — 17q21 risk variants alter CTCF binding sites and affect IL-2 production by T cells⁵⁵ 17q21 risk variants alter CTCF binding sites and affect IL-2 production by T cells
Nature Communications 2016 study showed that 17q21 SNPs switch CTCF insulator binding and reshape the local enhancer landscape, altering long-range gene regulation across the entire haploblock.

ORMDL3 is the best-characterized effector gene at this locus. It encodes an endoplasmic reticulum transmembrane protein that regulates sphingolipid synthesis⁶⁶ sphingolipid synthesis
ORMDL3 is a key regulator of serine palmitoyltransferase, the rate-limiting enzyme in de novo sphingolipid biosynthesis and ER stress responses. Overexpression of ORMDL3 elevates ER stress markers and activates NF-κB and STAT3 signaling, promoting airway inflammation. The GG genotype drives approximately 60% higher ORMDL3 expression than AA in airway cells.

The Evidence

The landmark Moffatt et al. 2007 GWAS⁷⁷ landmark Moffatt et al. 2007 GWAS
994 childhood asthma cases vs 1,243 controls; 17q21 SNPs showed p<10⁻¹²; ORMDL3 expression correlated most strongly of all 17q21 genes established this locus as the strongest GWAS signal for childhood asthma⁸⁸ strongest GWAS signal for childhood asthma
SNPs on chromosome 17q21 were found to be strongly and reproducibly associated with childhood-onset asthma ever identified at the time. The G allele (and GG genotype) confers asthma susceptibility via elevated ORMDL3 expression.

Counterintuitively, the same locus shows the opposite effect in autoimmune diseases⁹⁹ opposite effect in autoimmune diseases
Li et al. 2012 showed rs2872507 A allele is protective for asthma but a risk allele for rheumatoid arthritis, Crohn's disease, and ulcerative colitis. A multiethnic GWAS for rheumatoid arthritis confirmed rs2872507 at genome-wide significance¹⁰¹⁰ confirmed rs2872507 at genome-wide significance
rs2872507 reached p=1.7×10⁻⁹ across 16,659 RA cases and 49,174 controls in European and East Asian populations, with the A allele as the RA risk allele. The bioinformatic analyses from that study pointed to IKZF3-ORMDL3-GSDMB as the causal gene cluster.

IKZF3 variants at this locus are also associated with Graves' disease¹¹¹¹ associated with Graves' disease
rs2872507 A allele showed OR=1.27 (p=0.004) for Graves' disease; no association found with Hashimoto's thyroiditis in 604 GD and 311 HT patients vs 814 controls, suggesting that the A allele promotes anti-thyroid autoimmunity specifically. In Chinese Han populations, different IKZF3 SNPs in the same LD block (notably rs907091) showed associations with SLE susceptibility¹²¹² associations with SLE susceptibility
rs907091 CC genotype protective against SLE (OR=0.38, p=0.001); rs2872507 itself showed no significant SLE association in this population, illustrating that the pleiotropic effects of this locus vary by both ancestry and the specific disease.

A pharmacogenomics study found that the AA genotype responds best to inhaled corticosteroids¹³¹³ AA genotype responds best to inhaled corticosteroids
AA genotype showed 13.3% FEV1 improvement vs 7.0% for AG and 4.9% for GG after ICS therapy (p=0.0176) — a finding explained by lower baseline ORMDL3 expression in AA individuals, leaving more room for corticosteroid-mediated suppression.

Practical Implications

The clinical picture for rs2872507 depends on which end of the spectrum is relevant to you. For autoimmune disease risk (RA, Crohn's, Graves' thyroiditis), the A allele — and particularly the AA genotype — confers elevated risk through IKZF3/Aiolos-mediated effects on B cell activation and Th17 regulation. For asthma, the GG genotype is the risk profile; the A allele carriers have lower ORMDL3 expression and less airway hyperreactivity. In the autoimmune-inflammation context, carriers of the A allele should be alert to early signs of inflammatory arthritis, thyroid dysfunction, and intestinal inflammation, especially when combined with other autoimmune risk variants.

Periodic monitoring of inflammatory markers (CRP, ESR) and organ-specific autoantibody panels (anti-CCP for RA, anti-TPO for thyroid disease, calprotectin for intestinal inflammation) can enable early detection of subclinical autoimmunity at the stage when intervention is most effective.

Interactions

The 17q21 locus lies in strong LD, meaning rs2872507 is in linkage with multiple other functional variants including rs8076131, rs12936231, and rs907091. The independent RA risk in this region has been confirmed across rs2872507 alongside contributions from PTPN22 (rs2476601) and HLA loci. Because IKZF3/Aiolos directly regulates Th17 cell polarization — a central pathway in RA, Crohn's disease, and psoriatic arthritis — compound risk from multiple Th17-pathway variants (e.g. IL23R, IL17A variants in other categories) may amplify the effect. The rs2476601 (PTPN22 R620W) and rs2872507 (IKZF3) combination warrants compound action consideration given independent contributions to autoimmune risk through distinct but converging pathways (T-cell tolerance vs. Th17 differentiation).